TY - JOUR
T1 - Buspirone in social phobia
AU - Schneier, Franklin R.
AU - Saoud, Jihad B.
AU - Campeas, Raphael
AU - Fallon, Brian A.
AU - Hollander, Eric
AU - Coplan, Jeremy
AU - Liebowitz, Michael R.
PY - 1993/8
Y1 - 1993/8
N2 - The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We examined its efficacy in social phobia in a 12-week open trial. Twenty-one patients who met DSM-III-R criteria for social phobia and who did not respond to 1 week of single-blind placebo were treated with buspirone, and 17 completed a mini-mum of 2 weeks of treatment. Twelve of these 17 patients met criteria for the generalized subtype of social phobia. At week 12, 8(47%) of the 17 patients were rated much to very much improved in social phobia symptoms on the Clinical Global Impression Scale. Of the 12 patients who were able to tolerate a dose of 45 mg/day or more, 9 (67%) were at least much improved. Significant improvement was noted on measures of social anxiety and avoidance of social situations. Ratings of generalized anxiety and depression, which were low at baseline, did not change significantly during treatment. The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required.
AB - The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We examined its efficacy in social phobia in a 12-week open trial. Twenty-one patients who met DSM-III-R criteria for social phobia and who did not respond to 1 week of single-blind placebo were treated with buspirone, and 17 completed a mini-mum of 2 weeks of treatment. Twelve of these 17 patients met criteria for the generalized subtype of social phobia. At week 12, 8(47%) of the 17 patients were rated much to very much improved in social phobia symptoms on the Clinical Global Impression Scale. Of the 12 patients who were able to tolerate a dose of 45 mg/day or more, 9 (67%) were at least much improved. Significant improvement was noted on measures of social anxiety and avoidance of social situations. Ratings of generalized anxiety and depression, which were low at baseline, did not change significantly during treatment. The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required.
UR - http://www.scopus.com/inward/record.url?scp=0027325907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027325907&partnerID=8YFLogxK
U2 - 10.1097/00004714-199308000-00004
DO - 10.1097/00004714-199308000-00004
M3 - Article
C2 - 8376612
AN - SCOPUS:0027325907
SN - 0271-0749
VL - 13
SP - 251
EP - 256
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 4
ER -